Race and Socioeconomic Status in Anti-VEGF Treatment of Diabetic Macular Edema
| Autor: | Tyler E. Greenlee, Thais F. Conti, Nisha A. Malhotra, Grant L Hom, Justin Muste, Rishi P Singh |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Vascular Endothelial Growth Factor A
medicine.medical_specialty Diabetic Retinopathy business.industry Diabetic macular edema Angiogenesis Inhibitors Racial group Macular Edema Social Class Electronic health record Ranibizumab Internal medicine Intravitreal Injections Diabetes Mellitus medicine Humans Anti vegf treatment business Socioeconomic status Retrospective Studies |
| Zdroj: | Ophthalmic Surgery, Lasers and Imaging Retina. 52:578-585 |
| ISSN: | 2325-8179 2325-8160 |
| Popis: | BACKGROUND AND OBJECTIVE: Although people of low socioeconomic status (SES) and certain racial groups are at greater risk of developing diabetic macular edema (DME), the extent these high-risk groups experience treatment differences is unknown. This study characterizes anti-vascular endothelial growth factor (anti-VEGF) injection use for DME. PATIENTS AND METHODS: Data were collected from an electronic health record at the Cole Eye Institute, Cleveland Clinic Foundation for patients who received anti-VEGF treatment for DME between 2012 and 2019 ( N = 500). RESULTS: White patients on average received more injections over a 1-year period than Black patients (4.93 ± 3.14 vs 3.20 ± 2.43; P < .0001) and had fewer no-show appointments (1.39 ± 2.08 vs 3.23 ± 3.39; P < .0001). There is an association between living in communities with lower average incomes and receiving fewer anti-VEGF injections (3.06 ± 2.70 vs 4.88 ± 3.19; P = .005). CONCLUSIONS: DME treatment differs based on race and SES. Racial and SES associations with anti-VEGF injections present potential obstacles for delivering optimal ophthalmic care. [ Ophthalmic Surg Lasers Imaging Retina. 2021;52:578–585.] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|